SAN FRANCISCO, Jan. 1, 2019 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, will sponsor the world's
The World Economic Forum Annual Meeting brings together leaders of global society–the heads and members of more than 100 governments, top executives of the 1,000 foremost global companies, leaders of international organizations, and prominent thought leaders–to define priorities and shape global, industry, and regional agendas.
uBiome was chosen to join the Technology Pioneer community in 2018, composed of early-stage companies from around the world that are involved in the design, development, and deployment of new technologies and innovations, and are poised to have a significant impact on business and society. Previous recipients include Google, Foundation Medicine, Airbnb, Kickstarter, Spotify, and Twitter.
The microbiome is believed to have a profound effect on human health, including synthesizing vitamins, metabolizing nutrients, impacting immune response, and interacting with our hormones.
Given that recent research suggests microbes influence body systems and various health conditions, understanding and further manipulating these interactions may allow for better management and treatment of conditions.
"The microbiome is one of the most significant scientific discoveries of our age, regarded as a new organ of the human body, and it is proposed to revolutionize the future of healthcare. As such, the microbiome is of eminent importance to global thought-leaders," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "uBiome is honored to contribute cutting-edge insights to initiatives and world-critical discussions at the Annual Meeting by sponsoring the first Microbiome Conference at WEF."
To learn more about uBiome's accomplishments, please visit https://ubiome.com/news-press/.
About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; SmartFlu™, the world's first sequencing-based clinical respiratory test, which identifies more than 20 clinically relevant targets for viruses and bacteria associated with the flu and common cold; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
Subscribe to our Free Newsletters!